Your browser doesn't support javascript.
loading
New Protocol to Optimize iPS Cells for Genome Analysis of Fibrodysplasia Ossificans Progressiva.
Matsumoto, Yoshihisa; Ikeya, Makoto; Hino, Kyosuke; Horigome, Kazuhiko; Fukuta, Makoto; Watanabe, Makoto; Nagata, Sanae; Yamamoto, Takuya; Otsuka, Takanobu; Toguchida, Junya.
Affiliation
  • Matsumoto Y; Department of Tissue Regeneration, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
  • Ikeya M; Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
  • Hino K; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
  • Horigome K; Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
  • Fukuta M; Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
  • Watanabe M; iPS Cell-Based Drug Discovery Group, Innovative Drug Discovery Laboratories, Sumitomo Dainippon Pharma, Osaka, Japan.
  • Nagata S; Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
  • Yamamoto T; iPS Cell-Based Drug Discovery Group, Innovative Drug Discovery Laboratories, Sumitomo Dainippon Pharma, Osaka, Japan.
  • Otsuka T; Department of Tissue Regeneration, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
  • Toguchida J; Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Stem Cells ; 33(6): 1730-42, 2015 Jun.
Article in En | MEDLINE | ID: mdl-25773749
ABSTRACT
Successful in vitro disease-recapitulation using patient-specific induced pluripotent stem cells (iPSCs) requires two fundamental technical issues appropriate control cells and robust differentiation protocols. To investigate fibrodysplasia ossificans progressiva (FOP), a rare genetic disease leading to extraskeletal bone formation through endochondral ossification, gene-corrected (rescued) iPSC clones (resFOP-iPSC) were generated from patient-derived iPSC (FOP-iPSC) as genetically matched controls, and the stepwise induction method of mesenchymal stromal cells (iMSCs) through neural crest cell (NCC) lineage was used to recapitulate the disease phenotype. FOP-iMSCs possessing enhanced chondrogenic ability were transcriptionally distinguishable from resFOP-iMSCs and activated the SMAD1/5/8 and SMAD2/3 pathways at steady state. Using this method, we identified MMP1 and PAI1 as genes responsible for accelerating the chondrogenesis of FOP-iMSCs. These data indicate that iMSCs through NCC lineage are useful for investigating the molecular mechanism of FOP and corresponding drug discovery.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteogenesis / Genome, Human / Cell Differentiation / Chondrogenesis / Induced Pluripotent Stem Cells / Myositis Ossificans Limits: Humans Language: En Journal: Stem Cells Year: 2015 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteogenesis / Genome, Human / Cell Differentiation / Chondrogenesis / Induced Pluripotent Stem Cells / Myositis Ossificans Limits: Humans Language: En Journal: Stem Cells Year: 2015 Document type: Article Affiliation country: